Shares of Valeant Pharmaceuticals International Inc. (NYSE:VRX) traded up 3.4% during trading on Thursday . The stock traded as high as $23.07 and last traded at $22.35, with a volume of 34,726,015 shares changing hands. The stock had previously closed at $21.62.

Several analysts have recently commented on the stock. Rodman & Renshaw reissued a “buy” rating and set a $90.00 price target on shares of Valeant Pharmaceuticals International in a research note on Wednesday, July 6th. Stifel Nicolaus reissued a “buy” rating and set a $55.00 price target on shares of Valeant Pharmaceuticals International in a research note on Wednesday, July 6th. Wells Fargo & Co. reissued a “sell” rating on shares of Valeant Pharmaceuticals International in a research note on Wednesday, June 29th. BMO Capital Markets assumed coverage on shares of Valeant Pharmaceuticals International in a research note on Tuesday, June 28th. They set a “market perform” rating and a $26.00 price target on the stock. Finally, Royal Bank Of Canada reissued a “sector perform” rating on shares of Valeant Pharmaceuticals International in a research note on Monday, June 27th. Seven equities research analysts have rated the stock with a sell rating, fifteen have issued a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. Valeant Pharmaceuticals International currently has a consensus rating of “Hold” and a consensus price target of $66.43.

The company’s market capitalization is $7.84 billion. The stock has a 50 day moving average price of $23.51 and a 200-day moving average price of $49.66.

Valeant Pharmaceuticals International (NYSE:VRX) last released its earnings results on Tuesday, June 7th. The specialty pharmaceutical company reported $1.27 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.37 by $0.10. The company had revenue of $2.37 billion for the quarter, compared to the consensus estimate of $2.34 billion. The firm’s revenue for the quarter was up 9.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.36 EPS. On average, equities analysts forecast that Valeant Pharmaceuticals International Inc. will post $6.63 earnings per share for the current year.

In other Valeant Pharmaceuticals International news, CEO Joseph C. Papa acquired 202,000 shares of the stock in a transaction on Friday, June 10th. The shares were purchased at an average price of $24.48 per share, for a total transaction of $4,944,960.00. Following the completion of the acquisition, the chief executive officer now owns 2,442,199 shares in the company, valued at approximately $59,785,031.52. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Other hedge funds and institutional investors have added to or reduced their stakes in the company. Gulf International Bank UK Ltd increased its position in Valeant Pharmaceuticals International by 2.3% in the fourth quarter. Gulf International Bank UK Ltd now owns 97,223 shares of the specialty pharmaceutical company’s stock valued at $9,883,000 after buying an additional 2,230 shares during the last quarter. Dimensional Fund Advisors LP increased its position in Valeant Pharmaceuticals International by 3.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 79,777 shares of the specialty pharmaceutical company’s stock valued at $8,110,000 after buying an additional 2,500 shares during the last quarter. Deere & Co. increased its position in Valeant Pharmaceuticals International by 121.1% in the fourth quarter. Deere & Co. now owns 15,011 shares of the specialty pharmaceutical company’s stock valued at $1,526,000 after buying an additional 8,222 shares during the last quarter. Napier Park Global Capital US LP acquired a new position in Valeant Pharmaceuticals International during the fourth quarter valued at $1,740,000. Finally, Atlantic Trust Group LLC increased its position in Valeant Pharmaceuticals International by 79.7% in the fourth quarter. Atlantic Trust Group LLC now owns 40,283 shares of the specialty pharmaceutical company’s stock valued at $4,095,000 after buying an additional 17,868 shares during the last quarter.

Valeant Pharmaceuticals International, Inc is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.